Presentation of science and an update on the ILP100-development at Broad Institute by MIT and Harvard by Professor Mia Phillipson, May 19th in Boston
This week Professor Mia Phillipson is giving a presentation at the Broad Institute of MIT and Harvard in Boston about her research at Uppsala University in gut barrier, immune cell functions and how they can be targeted at the the Peyers Patches and giving an update on Ilya Pharmas ILP100-Oral program for patients experiencing ICI-induced colitis.
Data is presented by Andreas Fasth, Head of Clinical Development and Medical Affairs who will also participate in the two-day EWMA innovation forum with selected experts and stakeholders.
The value of regulatory interactions developing a new modality in gene therapy- presentation at ISCT Paris May 31 - June 3
The NMMP program aims to improve scientific networks and collaborations across Sweden, as well as to increase the awareness and accessibility of the cutting-edge infrastructure at SciLifeLab
Ilya Pharma have had a successful preIND meeting with the FDA related to the development of ILP100-Oral
Abstract selected for poster presentation at International Society for Cell- and Gene Therapy 2023 London May 2023
Abstract: The Value of early Regulatory Interactions with Authorities for emilimogene sigulactibac (INN) - a new modality in gene therapy, to be presented by Margareth Jorvid Head of Regulatory Affairs